|Bid||112.00 x 900|
|Ask||124.00 x 1000|
|Day's Range||113.76 - 131.91|
|52 Week Range||18.52 - 214.07|
|Beta (5Y Monthly)||0.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||153.75|
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Watchmaker Genomics today announced a broad partnership to enable innovative research across a wide range of high throughput sequencing applications including oncology and tumor profiling, inherited disease detection, liquid biopsy assays, and minimal residual disease monitoring.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced several events at the virtual 2021 Advances in Genome Biology and Technology (AGBT) meeting to be held March 1-3, 2021.
Twist Bioscience Corp (NASDAQ: TWST) has launched its NGS Methylation Detection System, end-to-end sample preparation, and target enrichment solution for identifying methylated regions in the human genome. DNA methylation plays a key role in many biological processes, including cancer. A methyl group can alter genetic behavior without changing the DNA sequence when present on a single nucleotide. In cancer methylation, patterns appear early, providing an approach for screening through liquid biopsy tests designed to detect a wide range of tumors from a single blood sample. Also, Twist has partnered with New England Biolabs (NEB), which have developed an enzyme-based alternative to sodium bisulfite treatment, EM-seqTM, for the preparation of samples for methylation analysis. Earlier this week, Twist Bioscience and China's Berry Genomics announced a partnership on next-generation sequencing target enrichment and library preparation tools. Price Action: TWST is up 2.02% at $138.02 in market trading hours on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaTwist Bioscience Collaborates With Australia Based Specialist Provider For Whole Exome Capture Assay© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.